Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Despite significant progress in the identification of mechanisms involved in motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS) and other motor system diseases, the actual pathogenesis and cause of these diseases remains unknown. Effective treatment of these diseases are dependent on the elucidation of their causes. The availability of diseased and control human tissues will be a critical resource for this research progress. . Samples of serum, spinal fluid, and urine from patients with motor system diseases can be used to study biochemical and genetic differences compared to tissues of neurologic disease controls and normal controls. Furthermore, the availability of autopsied CNS, PNS, as well as other tissues from patients with ALS or suspected ALS are useful for current and future research studies into the disease. Therefore, we propose to institute a Tissue Bank containing blood, urine, and cerebrospinal fluid donated from not only ALS and other motor neuron disease patients, but also those with other neurologic diseases and normals whose tissue can be used as controls. In addition there will be an autopsy band for post-mortem specimens of ALS and other motor neuron disease patients. Each specimen, whether from a living patient or autopsy will be de-identified and accompanied by a standard set of clinical information collected from the medical records in order that each specimen is characterized with the relevant clinical information to maximize the usefulness of the specimens.
Once established, this tissue bank will provide a resource in which a large number of samples will be readily available and expedite research by circumventing the delays in collecting specimens prospectively. These specimens will be used for research in the ALS Center of Hope at Drexel University College of Medicine and shared with any outside investigator with a valid IRB approved protocol.
| Condition |
|---|
|
Amyotrophic Lateral Sclerosis Neurodegenerative Disease Motor Neuron Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | ALS Tissue Donation Program |
- None Specified [ Time Frame: None Specified ] [ Designated as safety issue: No ]No primary outcome measure is specified for this study. Purpose of the study is to collect deidentified biological specimens which will be used to expedite other IRB approved studies.
Biospecimen Retention: Samples With DNA
Blood (Serum and DNA) Urine (Serum and DNA) CSF Blood specimens and tissue specimens (from brain, spinal cord, gastrointestinal tract, skeletal muscle and peripheral nerve)
| Estimated Enrollment: | 300 |
| Study Start Date: | April 2007 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
ALS
Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
|
|
Neuro
Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
|
|
Healthy
Normal Controls
|
| Autopsy |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
ALS clinic patients at MDA/ALS Center of Hope, along with families and caregivers. Also those with ALS who have donated their bodies to research.
Inclusion Criteria:
- Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
- Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
- Normal Controls
- In the case of spinal fluid collection, the patient will be undergoing a diagnostic lumbar puncture as part of the work-up
Exclusion Criteria:
- Any person with a non-neurologic chronic and poorly controlled systemic illness
Contacts and Locations| United States, Pennsylvania | |
| MDA/ALS Center of Hope | Recruiting |
| Philadelphia, Pennsylvania, United States, 19104 | |
| Contact: Christine Barr, RN 215-507-2585 cbarr@drexelmed.edu | |
| Principal Investigator: Terry Heiman-Patterson, MD | |
More Information
No publications provided
| Responsible Party: | Drexel University ( Drexel University College of Medicine ) |
| ClinicalTrials.gov Identifier: | NCT00716131 History of Changes |
| Other Study ID Numbers: | Internal-16827 |
| Study First Received: | July 14, 2008 |
| Last Updated: | March 1, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Drexel University:
|
Amyotrophic Lateral Sclerosis Cerebrospinal Fluid Neurodegenerative Disease Motor Neuron Disease |
Autonomic Nervous System Neurodegenerative Diseases Movement Disorders |
Additional relevant MeSH terms:
|
Amyotrophic Lateral Sclerosis Sclerosis Motor Neuron Disease Neurodegenerative Diseases Spinal Cord Diseases Central Nervous System Diseases |
Nervous System Diseases TDP-43 Proteinopathies Neuromuscular Diseases Proteostasis Deficiencies Metabolic Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on June 17, 2013